Januvia: Advanced DPP-4 Inhibitor for Effective Type 2 Diabetes Management
Januvia
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $5.33 | $160.00 (0%) | 🛒 Add to cart |
| 40 | $5.00 | $213.33 $200.00 (6%) | 🛒 Add to cart |
| 60 | $4.67 | $320.00 $280.00 (12%) | 🛒 Add to cart |
| 90 | $4.44
Best per pill | $480.00 $400.00 (17%) | 🛒 Add to cart |
Synonyms | |||
Januvia (sitagliptin phosphate) is an oral antihyperglycemic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, it works by enhancing the body’s own ability to lower elevated blood glucose levels through the incretin system. It is suitable for use as monotherapy or in combination with other glucose-lowering medications, including metformin, sulfonylureas, or insulin, when glycemic targets are not achieved with existing therapy alone. Januvia offers a mechanism of action that is glucose-dependent, reducing the risk of hypoglycemia when used without sulfonylureas or insulin.
Features
- Active ingredient: sitagliptin phosphate
- Available in 25 mg, 50 mg, and 100 mg film-coated tablets
- DPP-4 enzyme inhibitor class
- Once-daily dosing regimen
- Not associated with weight gain in clinical trials
- Renal dosage adjustment available for impaired kidney function
Benefits
- Effectively lowers HbA1c by enhancing glucose-dependent insulin secretion
- Reduces fasting and postprandial glucose levels with a low risk of hypoglycemia
- Provides a weight-neutral profile, unlike some other antidiabetic agents
- Convenient once-daily dosing supports medication adherence
- Suitable for combination therapy with other glucose-lowering drugs
- May preserve beta-cell function through incretin-mediated pathways
Common use
Januvia is commonly prescribed for the management of type 2 diabetes in adults when diet and exercise alone do not provide adequate glycemic control. It is often used as a second-line agent after metformin or as part of a combination regimen with other antidiabetic medications. Clinical studies support its use in various patient populations, including those with renal impairment (with dose adjustment) and elderly patients. It is not indicated for type 1 diabetes or diabetic ketoacidosis.
Dosage and direction
The recommended dose of Januvia is 100 mg once daily, with or without food. For patients with moderate renal impairment (eGFR 30 to less than 45 mL/min/1.73 m²), the dose is 50 mg once daily. For severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or end-stage renal disease requiring dialysis, the dose is 25 mg once daily. Tablets should be swallowed whole and not crushed or split. Dosage adjustments may be necessary when used concomitantly with certain other medications.
Precautions
Monitor renal function before initiation and periodically during treatment. Use with caution in patients with a history of pancreatitis. Assess volume status and renal function in patients experiencing dehydration. Not recommended during pregnancy unless potential benefit justifies potential risk. Use during lactation only if clearly needed. Elderly patients may require dose adjustment based on renal function. Periodic monitoring of liver function is advised, though hepatotoxicity is rare.
Contraindications
History of serious hypersensitivity reaction to sitagliptin or any component of Januvia, such as anaphylaxis or angioedema. Should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Contraindicated in severe gastrointestinal disease, including gastroparesis. Not recommended in patients with severe hepatic impairment due to limited clinical data.
Possible side effect
Common adverse reactions (≥5%) include nasopharyngitis, upper respiratory tract infection, and headache. Less frequently reported side effects include hypoglycemia (when used with sulfonylureas or insulin), pancreatitis, arthralgia, and hypersensitivity reactions such as urticaria. Rare cases of severe joint pain and bullous pemphigoid have been reported. Most side effects are mild to moderate in severity and often transient.
Drug interaction
No clinically significant interactions with metformin, glyburide, simvastatin, rosiglitazone, warfarin, or oral contraceptives. Caution advised with drugs that are strong CYP3A4 inducers (e.g., rifampin) as they may reduce sitagliptin concentrations. Monitor blood glucose when used with other glucose-lowering agents due to additive effects. Potential interaction with digoxin requires monitoring of digoxin levels.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If remembered at the time of the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Do not take a double dose to make up for a missed one. Consistent daily timing is recommended for optimal glycemic control.
Overdose
In the event of overdose, supportive measures should be instituted based on the patient’s clinical presentation. Hemodialysis may be effective in removing sitagliptin (approximately 13.5% removed over 3–4 hours). Symptoms of overdose may include hypoglycemia, especially if taken with other antidiabetic medications. Contact a poison control center for latest guidance.
Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Keep in the original container with the lid tightly closed to protect from moisture. Do not use if tablets are discolored or show signs of deterioration. Keep out of reach of children and pets. Do not flush unused medication; dispose of properly according to local regulations.
Disclaimer
This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient responses may vary. Full prescribing information should be reviewed before administration.
Reviews
Clinical trials demonstrate Januvia’s efficacy in reducing HbA1c by 0.5–0.8% as monotherapy and up to 1.0% in combination therapy. Patients report satisfaction with once-daily dosing and minimal side effects. Healthcare providers appreciate its weight-neutral profile and renal adjustment options. Long-term studies show sustained glycemic control over 2 years. Real-world evidence supports its use in diverse patient populations with type 2 diabetes.